Michael E. Rome - 13 Jun 2022 Form 4 Insider Report for Kinnate Biopharma Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 13 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2022, 17:00:29 UTC
Prior SEC filing: 06 Oct 2021
Next SEC filing: 05 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Mark A. Meltz, as attorney-in-fact

Key filing fact

Michael E. Rome filed Form 4 for Kinnate Biopharma Inc. on 15 Jun 2022.

Key facts

This page summarizes Michael E. Rome's Form 4 filing for Kinnate Biopharma Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2022, 17:00.

Change

Previous filing in this sequence was filed on 06 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNTE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +20,250
Change %
Price: $0.000000
Shares after: 20,250
Date: 13 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,250
Exercise price: $8.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date.